Approvals/NMPA/Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol

Approved

化学药品

Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol

LABORATOIRE GLAXOSMITHKLINE🇨🇳 National Medical Products Administration

Approval Id: 8ZY4lc7Fy3K
Approval Number: 国药准字HJ20140403
Generic Name: 沙美特罗替卡松吸入气雾剂
Generic Name En: Salmeterol Xinafoate and Fluticasone Propionate Inhalation Aerosol
Trade Name: 舒利迭
Drug Type: 化学药品
Dosage Form: 吸入气雾剂
Strength: 每瓶120揿，每揿含昔萘酸沙美特罗25μg（按C₂₅H₃₇NO₄计）和丙酸氟替卡松50μg，递送剂量为昔萘酸沙美特罗21μg（按C₂₅H₃₇NO₄计）与丙酸氟替卡松44μg。
Reg Date: 2024-04-18
Expired Date: 2029-04-17
Company Name: LABORATOIRE GLAXOSMITHKLINE
Production Company Name: GLAXO WELLCOME PRODUCTION
Company Detail Path: /organization/laboratoire-glaxosmithkline
Production Company Detail Path: /organization/glaxo-wellcome-production

Approved

Agency

NMPA

Country

🇨🇳

Approval Date

Apr 18, 2024

Approval ID

8ZY4lc7Fy3K

Type

化学药品